Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia in Patients with Relapsing Forms of Multiple Sclerosis
Treatment with Zeposia demonstrated a low annualized relapse rate of 0.103 and more than 70% of patients were relapse-free at four years Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up Bristol Myers Squibb today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile ...
Source: investingnews.com